Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

Alfie, who Duchenne Muscular Dystrophy, wants to walk on the pitch at a Liverpool FC game and watch a football match abroad.

Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s ...

Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the second quarter of 2025, beating the ...

Edgewise Therapeutics Inc., (Nasdaq: EWTX), a Boulder-based muscle-disease biopharmaceutical company, maintained a strong cash balance in the second quarter as it proceeds with trials for treatment of ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2025 and recent business highlights.

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.